GlassScriptPhysician profile
Leonard Kamen
NPI 1760577324
$44,444.49
in general payments reported to CMS, 2019-2025
25 companies · $130 in 2025
The $130 reported for 2025 was less than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36K · 2020: $4,680 · 2021: $2,350 · 2022: $472 · 2023: $346 · 2024: $368 · 2025: $130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $844.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $843.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biodelivery Sciences International, INC. | $31,437.46 | 2019-2021 | |
| Indivior INC. | $7,195.88 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,834.28 | 2019-2024 | Relistor |
| Biohaven Pharmaceuticals, INC. | $1,280.89 | 2021 | |
| Collegium Pharmaceutical, INC. | $465.27 | 2019-2025 | Belbuca |
| Abbvie INC. | $311.82 | 2021-2025 | |
| Lilly USA, LLC | $251.87 | 2019-2022 | |
| Ipsen Biopharmaceuticals, INC | $102.93 | 2019 | |
| Avanir Pharmaceuticals, INC. | $102.89 | 2019-2022 | |
| Grt US Holding, INC. | $65.48 | 2021-2022 | |
| Amgen INC. | $44.39 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $42.40 | 2021 | |
| Protega Pharmaceutials INC | $41.91 | 2023 | Roxybond |
| Radius Health, INC. | $36.42 | 2019 | |
| Almatica Pharma LLC | $27.14 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $24.84 | 2025 | |
| Pacira Pharmaceuticals Incorporated | $24.52 | 2024 | Iovera |
| Mdd US Operations, LLC | $24.23 | 2020 | |
| Pfizer INC. | $22.15 | 2025 | |
| Biogen, INC. | $22.00 | 2022 | |
| Allergan, INC. | $20.03 | 2022 | |
| Heron Therapeutics, INC. | $17.96 | 2024 | Zynrelef |
| Novartis Pharmaceuticals Corporation | $17.36 | 2019 | |
| Arbor Pharmaceuticals, INC. | $15.24 | 2019 | |
| Forte Bio-Pharma LLC | $15.13 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leonard Kamen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.